These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 33779082)
1. Clinical Impact of Natural Killer Group 2D Receptor Expression and That of Its Ligand in Ovarian Carcinomas: A Retrospective Study. Lee GH; An HJ; Kim TH; Kim G; Park KS; Park H; Lee TH; Kwon AY Yonsei Med J; 2021 Apr; 62(4):288-297. PubMed ID: 33779082 [TBL] [Abstract][Full Text] [Related]
2. MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. Cho H; Chung JY; Kim S; Braunschweig T; Kang TH; Kim J; Chung EJ; Hewitt SM; Kim JH BMC Cancer; 2014 Dec; 14():957. PubMed ID: 25510288 [TBL] [Abstract][Full Text] [Related]
3. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection. Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251 [TBL] [Abstract][Full Text] [Related]
4. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260 [TBL] [Abstract][Full Text] [Related]
5. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Sutherland CL; Rabinovich B; Chalupny NJ; Brawand P; Miller R; Cosman D Blood; 2006 Aug; 108(4):1313-9. PubMed ID: 16621962 [TBL] [Abstract][Full Text] [Related]
6. [Matrine enhances the cytotoxic sensitivity of ABCG2high nasopharyngeal carcinoma cells to natural killer cells by inducing high expression of NKG2D receptor ligands]. Huang YX; Wang Y; Sun M; Zhou XY; Deng L; Guo KY Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jul; 29(7):1329-32. PubMed ID: 19620045 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Li K; Mandai M; Hamanishi J; Matsumura N; Suzuki A; Yagi H; Yamaguchi K; Baba T; Fujii S; Konishi I Cancer Immunol Immunother; 2009 May; 58(5):641-52. PubMed ID: 18791713 [TBL] [Abstract][Full Text] [Related]
8. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells. Fernández-Messina L; Ashiru O; Agüera-González S; Reyburn HT; Valés-Gómez M J Cell Sci; 2011 Feb; 124(Pt 3):321-7. PubMed ID: 21224393 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma. Tsukagoshi M; Wada S; Yokobori T; Altan B; Ishii N; Watanabe A; Kubo N; Saito F; Araki K; Suzuki H; Hosouchi Y; Kuwano H Cancer Sci; 2016 Feb; 107(2):116-22. PubMed ID: 26608587 [TBL] [Abstract][Full Text] [Related]
10. Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. Vankayalapati R; Garg A; Porgador A; Griffith DE; Klucar P; Safi H; Girard WM; Cosman D; Spies T; Barnes PF J Immunol; 2005 Oct; 175(7):4611-7. PubMed ID: 16177106 [TBL] [Abstract][Full Text] [Related]
11. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. Kamimura H; Yamagiwa S; Tsuchiya A; Takamura M; Matsuda Y; Ohkoshi S; Inoue M; Wakai T; Shirai Y; Nomoto M; Aoyagi Y J Hepatol; 2012 Feb; 56(2):381-8. PubMed ID: 21756848 [TBL] [Abstract][Full Text] [Related]
12. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762 [TBL] [Abstract][Full Text] [Related]
13. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. Cao W; Xi X; Hao Z; Li W; Kong Y; Cui L; Ma C; Ba D; He W J Biol Chem; 2007 Jun; 282(26):18922-8. PubMed ID: 17470428 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical validation and expression profiling of NKG2D ligands in a wide spectrum of human epithelial neoplasms. Fujita H; Hatanaka Y; Sutoh Y; Suzuki Y; Oba K; Hatanaka KC; Mitsuhashi T; Otsuka N; Fugo K; Kasahara M; Matsuno Y J Histochem Cytochem; 2015 Mar; 63(3):217-27. PubMed ID: 25473094 [TBL] [Abstract][Full Text] [Related]
15. The HHV-6B U20 glycoprotein binds ULBP1, masking it from recognition by NKG2D and interfering with natural killer cell activation. Weaver GC; Schneider CL; Becerra-Artiles A; Clayton KL; Hudson AW; Stern LJ Front Immunol; 2024; 15():1363156. PubMed ID: 38953028 [TBL] [Abstract][Full Text] [Related]
16. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma. Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176 [TBL] [Abstract][Full Text] [Related]
17. [Expression of NKG2D ligands on dendritic cells at different development stages and its effect on cytotoxicity of NK cells]. Tu SF; Guo KY; Hu LS; Mei JZ; Zhou J; Sun M Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):341-3, 347. PubMed ID: 18394338 [TBL] [Abstract][Full Text] [Related]
18. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759 [TBL] [Abstract][Full Text] [Related]
19. Natural killer cell-mediated shedding of ULBP2. Wang R; Sun PD PLoS One; 2014; 9(3):e91133. PubMed ID: 24614922 [TBL] [Abstract][Full Text] [Related]
20. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]